NKCL Bio Group (Chairman Shin Dong-hwa) announced that it had obtained a U.S. patent for NK cell culture technology.
Recently, NKCL Bio Group successfully completed pre-clinical trials on the company's NK cell therapy pipeline for liver cancer, breast cancer, lung cancer, and kidney cancer using the technology, and also was honored to receive the 'Minister of Small and Medium Venture Business Award'.
In 2022, NKCL Bio Group successfully completed pre-clinical trials on NK cell culture-based immuno-oncology NK cell therapy pipelines in four areas. A CRO contract was signed for the main clinical trial in August last year, and phase 1/2a begins in 2023. Through this U.S. patent registration for core technology, advanced biopharmaceutical manufacturing license and cell processing facility license obtained from the Ministry of Food and Drug Safety in Korea, the company has completed verification of its technology and manufacturing facilities.
On the other hand, according to the market report (Source: GI), due to factors such as the increase in the use of NK cells for cancer and infection treatment and the improvement in awareness of immunotherapy, the global NK cell therapy market size is expected to continue high growth at an average annual growth rate of 40.9% between 2022 and 2029.